Recent advances in the management of atypical hemolytic uremic syndrome.
Clinical Internal Medicine, Division of Hematology, Wexner Medical Center, Ohio State University, Columbus, Ohio, USA.
Spero R
SR
Cataland
D051722:ADAM Proteins / Q000235:genetics / Q000378:metabolism; D000071120:ADAMTS13 Protein; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D065766:Atypical Hemolytic Uremic Syndrome; D015415:Biomarkers / Q000378:metabolism; D001792:Blood Platelets / Q000187:drug effects / Q000473:pathology; D003167:Complement Activation / Q000187:drug effects; D051056:Complement Inactivating Agents / Q000627:therapeutic use*; D003165:Complement System Proteins / Q000235:genetics* / Q000276:immunology; D003937:Diagnosis, Differential; D019468:Disease Management; D006463:Hemolytic-Uremic Syndrome / Q000150:complications / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D006801:Humans; D009154:Mutation; D010951:Plasma Exchange; D010976:Platelet Count; D011696:Purpura, Thrombocytopenic / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D051437:Renal Insufficiency / Q000209:etiology
D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D051056:Complement Inactivating Agents; D003165:Complement System Proteins; C481642:eculizumab; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human